Brightstar Therapeutics appoints Jared Young as new chief commercial officer

Image credit: BrightstarTherapeutics

Biotechnology company Brightstar Therapeutics has appointed a new chief commercial officer. With the company focusing on providing treatment options for corneal and ocular surface diseases, Jared Young will be aiding in expanding real-world evidence programs to promote the adoption of Brightstar’s BrightMEM corneal allograft for the treatment of limbal stem cell deficiency (LSCD) and persistent epithelial defects (PED), according to a news release.

“I am incredibly excited to join the Brightstar team at such a pivotal time,” said Young in the release. “The company’s dedication to advancing innovative therapies for corneal and ocular surface diseases is truly inspiring. I look forward to collaborating with this talented team to bring BrightMEM and other life-changing treatments to more doctors and patients.”

Young has more than 20 years of experience in healthcare sales and marketing, and was mostly recently serving as vice president of sales and marketing for CorneaGen. He has found success in closing a round of Series B financing, managed a strategic acquisition, and developed new programs to expand patient access to cornea transplants, the release said. Young also has experience in new product launches, marketing strategies, business development, and sales team leadership.¹

“We are thrilled to welcome Jared as our new Chief Commercial Officer. The combination of his industry experience and strategic vision makes him well-positioned to accelerate market penetration for BrightMEM, both in the US and internationally. Furthermore, Jared’s leadership will help us expand our product portfolio to address a wider range of ophthalmic conditions and solidify our position as a leading innovator in this field,” said Rajan Shukla, CEO of Brightstar Therapeutics.

In his new role at Brightstar, Young will also be leading the development of the overall commercial strategy for the company and responsible for driving growth, establishing strategic partnerships with large health systems and payers, and launching new products, according to the release.

Reference:

1. Brightstar Therapeutics appoints Jared Young chief commercial officer. News release. Brightstar Therapeutics. September 4, 2024. Accessed September 5, 2024. https://www.brightstartx.com/press?utm_medium=email&_hsenc=p2ANqtz--8mK5fnlJMrqdvBd2SHdsSmGFYWL22q2Gg9vQwWuKAcQqewcqNBjbmQBtecjI-eWJTyK8yqjMIrgSgnSKU_NBnKNmY8Q&_hsmi=323160510&utm_content=323160510&utm_source=hs_email